RSVpreF vaccine

BIOLOGICAL6 trials

Sponsors

Pfizer

Conditions

Respiratory Syncytial VirusRespiratory Syncytial Virus (RSV)Respiratory Syncytial Virus InfectionRespiratory Tract Infection

Phase 3

Safety and Immunogenicity of RSVpreF Coadministered With SIIV in Adults ≥65 Years of Age

CompletedNCT05301322

PfizerRespiratory Syncytial Virus

Start: 2022-04-13End: 2022-10-12Updated: 2023-10-27

A Study to Learn About the Vaccine RSVpreF In Pregnant Participants With HIV and Their Infants

CompletedNCT06325657

PfizerRespiratory Syncytial Virus

Start: 2024-03-12End: 2025-06-11Updated: 2026-07-02

A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Older Adults in Korea

CompletedNCT06593587

PfizerRespiratory Syncytial Virus

Start: 2024-10-07End: 2025-02-03Updated: 2026-02-09

A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Immunocompromised Adults

RecruitingNCT07768345

PfizerRespiratory Syncytial Virus (RSV)

Start: 2026-08-31End: 2028-02-02Target: 440Updated: 2026-09-08

Unknown Phase

SPECIAL INVESTIGATION FOR ABRYSVO IN PREGNANT WOMEN AND INFANTS

CompletedNCT06482099

PfizerRespiratory Tract Infection

Start: 2024-10-01End: 2026-02-27Updated: 2026-04-09

SPECIAL INVESTIGATION FOR ABRYSVO IN INDIVIDUALS AGED 60 YEARS OR OLDER

Active, not recruitingNCT06546800

PfizerRespiratory Syncytial Virus Infection

Start: 2025-05-27End: 2027-10-28Target: 1100Updated: 2026-02-04

Related Papers

A Randomized Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Bivalent RSVpreF Vaccine in Older Adults in Korea

Vaccines2026-09-03

Safety, Tolerability, and Immunogenicity of RSVpreF Vaccine in Pregnant Individuals Living with HIV.

2025-12-01

Safety and Immunogenicity of Bivalent RSVpreF Vaccine Coadministered With Seasonal Inactivated Influenza Vaccine in Older Adults

Clinical Infectious Diseases2023-11-2238 citations